July 2020 - Global Life Science Business Partnering - News & Updates

Highlights of July 2020

  1. Tata Capital to pick minority stake in Biocon Biologics for US$30 Million.
  2. Sun Pharma Acquires Canada's Aquinox Pharma for US$8.2 Million.
  3. Dr Reddy's partners with Fujifilm for COVID-19 drug.
  4. Biocon Biologics, Voluntis enter global collaboration on digital therapeutics for diabetes patients.
  5. Piramal Critical Care partners with Medivant Healthcare to supply injectable drugs in the US.
  6. Lipidor, Cadila Sign Agreement for Phase III Trial of AKP-02.
  7. Piramal Pharma Solutions announces integrated development programme with Bolt Biotherapeutics.
  8. Advent International has agreed to acquire a controlling stake in RA Chem Pharma Ltd from Bengaluru-based Micro Labs Ltd.
  9. Roche to pay Blueprint US$775 Million for Pralsetinib rights, setting up showdown with Lilly.
  10. Merck teams up with cancer startup Foghorn in US$425 Million deal.
  11. GSK hands CureVac US$294 Million to form mRNA infectious disease pact.
  12. Novartis, Sangamo team up on genetic meds for autism in US$75 Million deal.
  13. JDRF links with IQVIA for Type 1 diabetes diagnostic research partnership.
  14. Recursion Pharma acquires digital vivarium outfit Vium.

Highlights at Aagami

New Client Win: Silicon Valley based client has developed magnetic drug device platform that delivers minimally invasive and targeted treatment for hard to reach targets. Raised over $10M in non-dilutive grants & NIH contracts. Closed $2.33M in Series A. Aagami is supporting the client in their current $5M bridge to Series.

Aagami to attend (Digitally):

  • ChinaBio® Partnering Forum (August 25–27, 2020)
  • BioPharm America™ (September 21–24, 2020)
  • BIO-Europe® (October 26–29, 2020

Some of the partnering opportunities available at Aagami are:

For Acquisition

Spotlight: Mountain View Pharma (MVP) and its PharmaPEG® technology open for acquisition

  1. Creation of novel “BioBetters” to differentiate within the fast-growing biosimilars market
  2. Product life-cycle management with new intellectual property to extend market protection
  3. Company Acquisition would include

            - Novel patent portfolio

            - Data packages for >22 proteins, peptides and other therapeutics

            - U.S. and California NOL carry-forwards available for income-generating companies (Direct benefit of up to US$ 8.8 Million)

For Investors:

  1. Seeking up to US$10M in Current Tranche of Series B for US Innovator bringing Confluence of Portable MRI, Robotics & AI in a Physician's Office. The company has already raisedthe first tranche (May 15th, 2020) of Series B1 funding ($15M+). The client is now in the process of doing a second close on the Series B-1 round in August and have commitments from several existing investors and new investors, such as Philip Dolan, Kineticos, and MicroPort.
  2. Seeking up to $5M bridge to Series B at $16M cap for a magnetic drug device platform that delivers minimally invasive and targeted treatment to hard to reach targets. Use of proceeds: IND submission, Phase 1 study. Raised over $10M in non-dilutive grants & NIH contracts. Closed $2.33M in Series A
  3. Seeking US$1.5M for Drug-device to delay the progression of Parkinson’s disease (PD), prevent Asian Flush and Hangover.
  4. Seeking US$1M for expansion of an Oncology focused healthcare and data science company.

For Licensing/Partnering/Co-development:

  1. Selection Technology using Bacteriocin-Immunity for Improved Microbial (E. coli.) Fermentation.
  2. On the Market Pro-immunity anti-cancer capsules of Rapid and synchronized dormancy-broken Kyoho grape seed endosperm from our Japanese client.
×
Twitter